CN102216322A - 用基于氢键替代的螺旋抑制HIF-1α和p300/CBP之间的相互作用 - Google Patents

用基于氢键替代的螺旋抑制HIF-1α和p300/CBP之间的相互作用 Download PDF

Info

Publication number
CN102216322A
CN102216322A CN2009801461214A CN200980146121A CN102216322A CN 102216322 A CN102216322 A CN 102216322A CN 2009801461214 A CN2009801461214 A CN 2009801461214A CN 200980146121 A CN200980146121 A CN 200980146121A CN 102216322 A CN102216322 A CN 102216322A
Authority
CN
China
Prior art keywords
peptide
ala
asn
arg
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801461214A
Other languages
English (en)
Chinese (zh)
Inventor
P·阿罗拉
B·奥伦宇克
R·N·查普曼
L·亨切
K·M·布洛克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Arizona State University ASU
Original Assignee
New York University NYU
Arizona State University ASU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU, Arizona State University ASU filed Critical New York University NYU
Publication of CN102216322A publication Critical patent/CN102216322A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2009801461214A 2008-09-18 2009-09-18 用基于氢键替代的螺旋抑制HIF-1α和p300/CBP之间的相互作用 Pending CN102216322A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9819308P 2008-09-18 2008-09-18
US61/098,193 2008-09-18
PCT/US2009/057592 WO2010033879A2 (en) 2008-09-18 2009-09-18 Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices

Publications (1)

Publication Number Publication Date
CN102216322A true CN102216322A (zh) 2011-10-12

Family

ID=42040175

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801461214A Pending CN102216322A (zh) 2008-09-18 2009-09-18 用基于氢键替代的螺旋抑制HIF-1α和p300/CBP之间的相互作用

Country Status (9)

Country Link
US (1) US9399666B2 (https=)
EP (1) EP2344520B1 (https=)
JP (2) JP2012503013A (https=)
CN (1) CN102216322A (https=)
AU (1) AU2009293020A1 (https=)
BR (1) BRPI0919414A2 (https=)
CA (1) CA2737614A1 (https=)
ES (1) ES2446249T3 (https=)
WO (1) WO2010033879A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2997973A1 (en) * 2006-11-15 2016-03-23 Dana-Farber Cancer Institute, Inc. Stabalized maml peptides and uses thereof
BRPI0720306A2 (pt) 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
ES2649941T3 (es) 2007-02-23 2018-01-16 Aileron Therapeutics, Inc. Aminoácidos sustituidos para preparar péptidos macrocíclicos unidos a triazol
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
WO2010033879A2 (en) 2008-09-18 2010-03-25 New York University Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices
CA2737922A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
US8511577B2 (en) 2011-02-24 2013-08-20 Nest Labs, Inc. Thermostat with power stealing delay interval at transitions between power stealing states
ES2586411T3 (es) 2011-03-04 2016-10-14 New York University Macrociclos sustitutos de enlace de hidrógeno como moduladores de Ras
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9376469B2 (en) 2011-12-21 2016-06-28 New York University Proteolytically resistant hydrogen bond surrogate helices
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US20140205681A1 (en) * 2013-01-19 2014-07-24 New York University HYDROGEN-BOND SURROGATE PEPTIDES AND PEPTIDOMIMETICS FOR p53 REACTIVATION
WO2014113794A2 (en) * 2013-01-19 2014-07-24 New York University Oligooxopiperazines for p53 reactivation
US20150065436A1 (en) * 2013-09-03 2015-03-05 University Of Southern California INHIBITING INTERACTION BETWEEN HIF-1ALPHA AND p300/CBP WITH HYDROGEN BOND SURROGATE-BASED HELICES
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
WO2018008984A1 (ko) * 2016-07-05 2018-01-11 이화여자대학교 산학협력단 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118620A2 (en) * 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
JP2008096423A (ja) * 2006-10-12 2008-04-24 Korea Advanced Inst Of Sci Technol ＨＩＦ−１αＣ−末端ペプチドとＣＢＰまたはｐ３００蛋白質間の結合を定量分析する方法、及び前記方法を利用した抑制剤のスクリーニング方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6986881B1 (en) 1999-06-04 2006-01-17 Dana-Farber Cancer Institute, Inc. Identification of compounds that modify transcriptional responses to hypoxia
GB0211920D0 (en) 2002-05-23 2002-07-03 Isis Innovations Ltd Assay
ITMI20042477A1 (it) 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl Uso di antibiotici a strutura dichetoditiopiperazinica per la preparazione di composizioni farmaceutiche antiangiogeniche
WO2010033879A2 (en) 2008-09-18 2010-03-25 New York University Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices
US20120115783A1 (en) * 2008-09-22 2012-05-10 Alleron therapeutics, Inc Peptidomimetic macrocycles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118620A2 (en) * 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
US20060014675A1 (en) * 2004-05-27 2006-01-19 Paramjit Arora Methods for preparing internally constrained peptides and peptidomimetics
JP2008096423A (ja) * 2006-10-12 2008-04-24 Korea Advanced Inst Of Sci Technol ＨＩＦ−１αＣ−末端ペプチドとＣＢＰまたはｐ３００蛋白質間の結合を定量分析する方法、及び前記方法を利用した抑制剤のスクリーニング方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FREEDMAN ET AL: "Accession Number：1L3E_A，Chain A, Nmr Structures Of The Hif-1alpha Ctad P300 CH1 COMPLEX", 《GENBANK》 *
ROSS N. CHAPMAN ET AL: "Optimized Synthesis of Hydrogen-Bond", 《ORGANIC LETTERS》 *
STEVEN J. FREEDMAN ET AL: "Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α", 《PNAS》 *

Also Published As

Publication number Publication date
JP2012503013A (ja) 2012-02-02
WO2010033879A2 (en) 2010-03-25
EP2344520B1 (en) 2013-11-13
EP2344520A2 (en) 2011-07-20
US9399666B2 (en) 2016-07-26
AU2009293020A1 (en) 2010-03-25
US20110245175A1 (en) 2011-10-06
EP2344520A4 (en) 2012-03-14
JP2015061833A (ja) 2015-04-02
ES2446249T3 (es) 2014-03-06
CA2737614A1 (en) 2010-03-25
WO2010033879A3 (en) 2010-07-15
BRPI0919414A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
CN102216322A (zh) 用基于氢键替代的螺旋抑制HIF-1α和p300/CBP之间的相互作用
US12097237B2 (en) Small molecule Ras inhibitors
JP7095035B2 (ja) 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート
US20020048271A1 (en) Methods and composition for restoring conformational stability of a protein of the p53 family
EP2814821B1 (en) Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics
US12528846B2 (en) BH4 stabilized peptides and uses thereof
KR20180096621A (ko) 암의 치료용 조합물
Gaston et al. Voltage-gated potassium channel proteins and stereoselective S-nitroso-l-cysteine signaling
JP2012504619A (ja) 肥満および糖尿病の有望な治療薬としてのグレリンｏ−アシルトランスフェラーゼ阻害剤の合成方法および使用方法
JP2021501201A (ja) ステープルペプチドの細胞内送達のためのポリペプチド接合体
WO2019094830A1 (en) Mitofusin modulation agents and methods of use thereof
Zou et al. Cyclic peptide Keap1–Nrf2 protein–protein interaction inhibitors: design, synthesis, and in vivo treatment of acute lung injury
JP2007505145A (ja) ニューロンの成長を調節する化合物およびそれらの使用
KR102658844B1 (ko) 펩티드 유도체 및 약학적 조성물
EP3033094A1 (en) Map kinase p38 binding compounds
AU2015202742A1 (en) Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices
US20130345143A1 (en) MODULATION OF p62 FUNCTION THROUGH THE PB1 DOMAIN
Kaplan Identification and Biophysical Characterization of Small Molecules Modulating Protein Disulfide Isomerase in Neurodegenerative Diseases
JPWO2006090555A1 (ja) Ａｋｔ活性化剤
Jacobs Structural modifications to DNA-binding polyamides for improved biological activity in cell culture
EP1854509A2 (en) Methods and compositions for restoring conformational stability of a protein of the p53 family
EP1484060A2 (en) Methods and compositions for restoring conformational stability of a protein of the p53 family

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20111012